

# Clinical trials of dalcetrapib

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 cardiovascular prevention

| Trial  | Treatments   | Patients  | Trials design and methods                       |
|--|--|---|---|
| <b>dalcetrapib vs placebo</b>  |  |   |   |
| <a href="#">dal-VESSEL , 2011</a><br>n=NA<br>follow-up: 12 weeks   | dalcetrapib 600 mg daily<br>versus<br>placebo  | men and women with coronary heart disease or coronary heart disease risk equivalents with HDL-cholesterol levels <50 mg/dL  | Parallel groups<br>double-blind                 |
| <a href="#">dal-OUTCOMES , 2012</a><br>[NCT00658515]<br>n=7938/7933<br>follow-up: 31 monthsh<br>(median) | dalcetrapib 600 mg daily beginning 4 to 12 weeks after an index ACS event<br>versus<br>placebo | patients with recent acute coronary syndrome  | Parallel groups<br>double-blind<br>27 countries |
| <b>dalcetrapib vs</b>  |  |   |   |
| <a href="#">NCT01516541</a> <i>ongoing</i><br>[NCT01516541]<br>n=2220<br>follow-up:                      | dalcetrapib 600 mg orally daily<br>versus<br>placebo   | patients with stable coronary heart disease (CHD), with CHD risk equivalents or at elevated risk for cardiovascular disease |   |
| <a href="#">NCT01059682</a> <i>ongoing</i><br>[NCT01059682]<br>n=936<br>follow-up:                       | dalcetrapib 600 mg orally once a day<br>versus<br>placebo                                      | subjects undergoing coronary angiography who have coronary artery disease   |   |

More details and results :

- CEPT inhibition for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q340>
- HDL increasing drugs for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q503>

## References

**dal-VESSEL, 2011:**

**dal-OUTCOMES, 2012:**

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009 Dec;158:896-901.e3 [19958854]

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2012 Nov 5; [23126252] [10.1056/NEJMoa1206797](https://doi.org/10.1056/NEJMoa1206797)

**NCT01516541, :**

ongoing trial NCT01516541

**NCT01059682, :**

ongoing trial NCT01059682